Pfizer

July 28 (Reuters) - Pfizer Ltd PFIZ.NS:

• JUNE-QUARTER NET PROFIT 2.04 BILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 6.53 BILLION RUPEES

Further company coverage: PFIZ.NS

(([email protected];;))

Pfizer Ltd announced that its Executive Director – Finance and Chief Financial Officer, Amit Agarwal, has resigned to pursue an opportunity outside the company. Mr Agarwal will continue in his current role until the close of business on October 8, 2026, providing a notice period of more than two months. He will also step down from the board of directors and relinquish his memberships on the corporate social responsibility, risk management, and board administrative committees on the same date. The company did not name a successor or disclose any disagreements leading to the separation. Mr Agarwal joined the board and held the CFO position; his resignation letter cited a decision to pursue another professional opportunity.

Powered by Tijori

By Mrinalika Roy

July 16 (Reuters) - U.S. drugmaker Pfizer PFE.N has temporarily discontinued Premarin vaginal cream in India, shrinking estrogen therapy options for millions of women experiencing menopause-related symptoms in the country.

The decision was driven by "certain supply challenges," said Trupti Wagh, Pfizer's senior director of media relations for APAC, on Thursday. She added that the company is exploring options to resume supply as soon as possible.

Pfizer has not previously disclosed the discontinuation.

The treatment contains a mixture of estrogen hormones and is prescribed to treat vaginal dryness, painful intercourse and other symptoms of menopause caused by declining estrogen levels.

The cream, which is sold across the globe including in the U.S., Canada and Singapore, has become an important treatment option in India.

Data from Pune-headquartered research firm Pharmarack showed more than 620,000 units of the cream were sold in the 12 months ended June 2026, representing over half of all units sold in the category.

Premarin vaginal cream generated sales of about 266 million rupees ($2.76 million) in that period, accounting for about 37% of India's conjugated estrogen market by value. Sales have more than quadrupled from about 62 million rupees in 2022.

The suspension could leave patients with limited alternatives in India, where treatment options for genitourinary syndrome of menopause (GSM) are already scarce.

"Globally, we have a huge range of products available for women with GSM ... creams, ovules, vaginal rings. In India, we have essentially only Premarin and Evalon, an estriol-based vaginal cream marketed by Torrent Pharmaceuticals," said Dr Sukhpreet Patel, a gynecologist and founder of MenopauseWize, a menopause education and advocacy platform.

Patel said she began hearing complaints from patients late last year that they were unable to obtain Premarin, and initially assumed the problem was linked to broader global shortages of hormone therapies.

Reuters has previously reported shortages of estrogen patches and progesterone capsules in the U.S. as demand for menopause treatment surges.

Premarin cream is currently listed as "out of stock" on several popular online pharmacies in India, including MedPlus Mart, Reliance Industries' Netmeds, Truemeds and Tata 1MG.

India accounted for about 2.8% of the global estrogen replacement therapy market in 2025, according to market research firm Grand View Research.

The market generated an estimated $334.5 million in revenue that year and is projected to grow to $604.6 million by 2033, reflecting increasing awareness and treatment of menopause-related symptoms in the country.

Patel said more women had been contacting her seeking alternatives, adding that local estrogen therapies are particularly important for patients who do not require or wish to use systemic hormone replacement therapy.

According to estimates cited by the Indian Menopause Society, India is expected to have about 400 million women aged 45 and older by 2026. Despite the large patient population, awareness and treatment rates remain low.

($1 = 96.3450 Indian rupees)

(Reporting by Mrinalika Roy in Bengaluru; editing by Caroline Humer and Anil D'Silva)

(([email protected];))

May 12 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER LTD DECLARES DIVIDEND OF 75 RUPEESPER SHARE

• PFIZER MARCH-QUARTER NET PROFIT 2 BILLION RUPEES

• PFIZER LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 6.29 BILLION RUPEES

Source text: ID:nnAZN4SVR46

Further company coverage: PFIZ.NS

(([email protected];;))

April 24 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER LTD - RECEIVES TAX DEMAND OF 857.4 MILLION RUPEES FOR FY 2022-23

• PFIZER LTD - INCOME-TAX DEPARTMENT ISSUES SHOW CAUSE NOTICE FOR PENALTY PROCEEDINGS

• PFIZER LTD - DOES NOT EXPECT MATERIAL IMPACT FROM TAX ORDER AT THIS STAGE

Source text: ID:nBSEbN2pJV

Further company coverage: PFIZ.NS

(([email protected];))

** Shares of Pfizer PFIZ.NS rise as much as 8.1% to 5,442 rupees

** Parent Pfizer Inc PFE.N agreed to lower prescription drug prices in the Medicaid program in deal cut with Trump

** PFIZ later trims to 2.7% gain

** ICICI Direct Research says other branded players likely to negotiate pricing to get respite from tariffs

** Notes it as an opportunity for contract development and manufacturing organisation players, especially for those having a U.S. manufacturing base

** More than 243,000 shares traded so far, 11.5x their 30-day moving avg; busiest day yet since Aug

** YTD, PFIZ down 2.5%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Pfizer PFIZ.NS rises 5.3% to 5,379 rupees

** Pharmaceuticals co's Q1 net profit rises 27.2% y/y; revenue up 7.1% y/y

** Stock sees most active session since May 20, with 278,147 shares traded - more than 9x the 30-day avg

** YTD, PFIZ gains ~4%

(Reporting by Vijay Malkar)

(([email protected];))

Aug 13 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER JUNE-QUARTER NET PROFIT 1.92 BILLION RUPEES

• PFIZER JUNE-QUARTER REVENUE FROM OPERATIONS 6.03 BILLION RUPEES

Source text: ID:nBSEk25CX

Further company coverage: PFIZ.NS

(([email protected];))

Aug 11 (Reuters) - Pfizer Ltd PFIZ.NS:

• LAUNCH OF PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (ADSORBED) I.P., 20

Source text: ID:nBSE7vsGqC

Further company coverage: PFIZ.NS

(([email protected];;))

** Shares of Pfizer Ltd PFIZ.NS jump 11% to 4,960 rupees

** 'Gelusil' antacid maker's fourth-quarter consol net profit surges 85%; rev from ops up 8%

** PFIZ recorded a one-time gain of 1.73 billion rupees ($20.3 million) from sale of a property

** Adjusting for the one-time gain, profit before exceptional items and tax rose 4% Y/Y

** Stock trims YTD losses to 6%

($1 = 85.4470 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

March 19 (Reuters) - Pfizer Ltd PFIZ.NS:

• LIC CUTS STAKE IN PFIZER TO 4.026% FROM 6.052% - EXCHANGE FILING

Source text: ID:nBSEbtwH6P

Further company coverage: PFIZ.NS

(([email protected];))

Jan 31 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER DEC-QUARTER NET PROFIT 1.28 BILLION RUPEES

• PFIZER DEC-QUARTER REVENUE FROM OPERATIONS 5.38 BILLION RUPEES

Source text: ID:nBSE5kQk0R

Further company coverage: PFIZ.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS rise as much as 5% to 317.50 rupees

** Co gets U.S. FDA approval for varenicline tablets, which are used to help quit smoking

** INRM last up about 2%, set to snap nine-session losing streak

** Stock still down ~22% so far this year, on track for third straight year of losses

** YTD, peers Pfizer Ltd PFIZ.NS and Ajanta Pharma AJPH.NS up ~20% and ~43%, respectively

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Oct 28 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER LTD SEPT-QUARTER NET PROFIT 1.58 BILLION RUPEES

• PFIZER LTD SEPT-QUARTER REVENUE FROM OPERATIONS 5.89 BILLION RUPEES

Source text: [ID:]

Further company coverage: PFIZ.NS

(([email protected];))

Oct 8 (Reuters) - Pfizer PFE.N CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)

(([email protected];))

Oct 6 (Reuters) - Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer PFE.N and wants the U.S. drug giant to make changes to turn its performance around, the Wall Street Journal reported on Sunday.

(Reporting by Surbhi Misra in Bengaluru; Editing by Tom Hogue)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

** Shares of Pfizer Ltd PFIZ.NS, Indian unit of pharma firm Pfizer Inc PFE.N, up as much as 5.3% at 5,651.3 rupees, highest since Oct 2021

** Co's June-qtr profit up ~61% YoY, revenue rises 5.9%

** Analysts' rating on PFIZ, on avg, is "hold", PT is 4,797.50 rupees - LSEG data

** PFIZ eyes second biggest monthly rise since Oct 2021

** Stock up ~29% YTD, on track for a second straight session of gains

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected]))

July 29 (Reuters) - Pfizer Ltd PFIZ.NS:

• JUNE-QUARTER NET PROFIT 1.51 BILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 5.63 BILLION RUPEES

Further company coverage: PFIZ.NS

(([email protected];))

May 17 (Reuters) - Pfizer Ltd PFIZ.NS:

• PFIZER LTD - DIVIDEND 35 RUPEESPER SHARE

• PFIZER LTD MARCH-QUARTER NET PROFIT 1.79 BILLION RUPEES VERSUS PROFIT 1.3 BILLION RUPEES

• PFIZER LTD MARCH-QUARTER REVENUE FROM OPERATIONS 5.47 BILLION RUPEES VERSUS 5.73 BILLION RUPEES

Source text for Eikon: ID:nNSEb7YxzX

Further company coverage: PFIZ.NS

(([email protected];;))

** Shares of Pfizer Ltd PFIZ.NS, Indian unit of Pfizer Inc PFE.N, down 3.7% at 4,347.85 rupees

** Stock on track for worst day since Feb. 13, 2023, and to fall for a third straight session

** Co's Q3 profit fell ~14% YoY

** Rivals Abbott India ABOT.NS and GlaxoSmithKline Pharma GLAX.NS posted higher Q3 profits, sending shares up

** Avg analyst rating on PFIZ is "strong buy", GLAX rated "hold" and ABOT rated "buy" - LSEG data

** PFIZ's avg PT is 4,519.83 rupees - LSEG data

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Jan 22 (Reuters) - Pfizer Ltd PFIZ.NS:

• NAMES AMIT AGARWAL AS CFO

Source text for Eikon: ID:nBSE1rg98y

Further company coverage: PFIZ.NS

(([email protected];))

Dec 26 (Reuters) - Pfizer Ltd PFIZ.NS:

• GOT ORDER FROM DEPUTY COMMISSIONER FOR TAX

• TOTAL DEMAND OF 16.7 MILLION RUPEES

• GOT ONE MORE ORDER FROM CGST & CX FOR DEMAND OF 7.7 MILLION RUPEES

Further company coverage: PFIZ.NS

(([email protected];))

** India's pharmaceutical sector growth slowed to 2.9% year-on-year in November from 13.7% in October as volumes drop, data from All India Origin Chemists and Distributors (AIOCD) showed

** Volumes in November down 4.5% year-on-year after rising 5% in the previous month

** Dermatology and opthalmology segments witness fall in sales while anti-infectives, cardiac, respiratory segments see rise in sales in November

** Eris Lifesciences ERIS.NS, Cipla CIPL.NS, Torrent Pharmaceuticals TORP.NS, Sun Pharmaceutical Industries SUN.NS and Glenmark Pharmaceuticals GLEN.NS see sales uptick of 7% to 11%, outperforming the Indian pharma market

** FDC FDC.NS, Alembic Pharma ALEM.NS, GlaxoSmithKline Pharmaceuticals GLAX.NS and Mankind Pharma MNKI.NS underperform the industry, in terms of November sales

** Pfizer PFIZ.NS sees sales decline of 11.9% while Sanofi India SANO.NS posts 5.7% monthly sales drop

** Nifty pharma index .NIPHARM down 0.9% on the day, dragged by 5% drop in Dr. Reddy's Laboratories REDY.NS on U.S. drug regulator's observations on the drug maker's facility at Hyderabad

** Pharma index up 27% in 2023 so far, compared with 16% rise in Nifty 50 index .NSEI

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Nov 30 (Reuters) - Pfizer Ltd PFIZ.NS:

• MILIND PATIL, CHIEF FINANCIAL OFFICER OF COMPANY HAS RETIRED

Source text for Eikon: ID:nBSEbgC0Ps

Further company coverage: PFIZ.NS

(([email protected];))

Aug 16 (Reuters) - Seagen SGEN.O said on Wednesday its cancer therapy in combination with Roche's ROG.S Kadcyla helped control disease progression in a late-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

BENGALURU, Aug 9 (Reuters) - Abbott India ABOT.NS, the Indian arm of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 41% rise in its first-quarter profit on Wednesday, driven by strong sales in its mainstay pharmaceuticals segment.

The company, which makes pain-reliever ibuprofen under the brand name Brufen, said its profit rose to 2.90 billion rupees ($35.02 million), compared with 2.06 billion rupees a year earlier.

Revenue from operations rose 13.4% to 14.79 billion rupees for the quarter.

For further earnings highlights, click here.

KEY CONTEXT

Abbott India, for which the pharmaceutical segment is the sole revenue generator, develops and distributes over 600 products in India, including vitamins, anti-allergic drugs and consumer care.

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales.

Last month, peer GlaxoSmithKline Pharmaceuticals GLAX.NS posted an 11% rise in its first-quarter profit, helped by a steady vaccines business.

PEER COMPARISON

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

APRIL TO JUNE STOCK PERFORMANCE

-- All data from Refinitiv

-- $1 = 82.8150 Indian rupees

(Reporting by Kashish Tandon and Biplob Kumar Das in Bengaluru; Editing by Janane Venkatraman)

(([email protected];))

May 18 (Reuters) - Pfizer Ltd PFIZ.NS:

• VOLUNTARY RECALL IS LIKELY TO HAVE AN IMPACT ON THE REVENUE AND PROFITABILITY OF THE CO

• PRODUCTS RECORDED SALE OF 1.39 BILLION RUPEES FOR YEAR ENDED ON MARCH 31, 2023

Source text for Eikon: ID:nNSE4LK27R

Further company coverage: PFIZ.NS

(([email protected];;))

BENGALURU, May 15 (Reuters) - Pfizer Ltd PFIZ.NS, the Indian unit of U.S. pharmaceutical group Pfizer Inc PFE.N, on Monday reported a 3.1% rise in fourth-quarter profit, helped by lower raw material expenses.

Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2%.

Pfizer also declared a final dividend of 35 rupees per share and a special dividend of 5 rupees per share.

For further earnings highlights, click: nFWN37C0WS

WHY IT MATTERS

Pfizer's pharmaceutical segment has a portfolio of over 150 products. Separately, parent Pfizer Inc reported higher-than-expected first-quarter revenue and profit, helped by demand for its COVID-19 products.

In India, rival Cipla Ltd CIPL.NS posted a 45.2% increase in fourth-quarter profit, while Novartis India Ltd NOIN.NS reported a quarterly profit compared with a loss a year ago.

Abbott India Ltd ABOT.NS and GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS are scheduled to report its quarterly results later this week.

COMPETITOR COMPARISON

* The mean of analyst ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

JAN-MARCH STOCK PERFORMANCE

-- All data from Refinitiv

-- $1 = 81.7800 Indian rupees

(Reporting by Rama Venkat in Bengaluru; Editing by Varun H K)

(([email protected]; https://twitter.com/ramavenkat0607; +91 8095218099;))